STOCK TITAN
  1. Home
  2. Sec-filings
  3. DNLI
  4. [Form 4] Denali Therapeutics Inc. Insider Trading Activity

Denali Therapeutics (DNLI) COFO sells 2,857 shares to cover RSU taxes

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Denali Therapeutics Inc. officer Alexander O. Schuth reported selling 2,857 shares of common stock on 2026-08-11 at $25.07 per share, with a footnote stating the shares were sold to satisfy tax obligations related to previously vested RSUs. Following this transaction, he directly holds 281,763 shares, including 135,475 unvested RSUs and 1,792 shares acquired under the ESPP on June 1, 2026, and indirectly holds 523,749 shares through The Schuth Family Trust, where he serves as trustee. The filing indicates the transaction was not made under a Rule 10b5-1 trading plan.

Positive

  • None.

Negative

  • None.
Insider Schuth Alexander O.
Role COFO and Secretary
Sold 2,857 shs ($72K)
Type Security Shares Price Value
Sale Common Stock F1, F2, F3 2,857 $25.07 $72K
holding Common Stock F4 -- -- --
Holdings After Transaction: Common Stock — 281,763 shares (Direct); Common Stock — 523,749 shares (Indirect, See footnote)
Footnotes (4)
  1. F1. Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested RSUs.
  2. F2. Includes 135,475 Unvested RSUs.
  3. F3. Includes 1,792 shares acquired under the ESPP Purchase on June 1, 2026.
  4. F4. The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.
Shares sold 2,857 shares Common stock sale reported on 2026-08-11
Sale price $25.07 per share Price for 2,857 DNLI shares sold on 2026-08-11
Direct holdings after sale 281,763 shares Direct DNLI common stock held following the transaction
Indirect holdings (trust) 523,749 shares Shares held by The Schuth Family Trust with Schuth as trustee
Unvested RSUs included 135,475 RSUs Unvested RSUs counted within direct holdings after the sale
ESPP shares 1,792 shares Shares acquired under ESPP purchase on June 1, 2026
RSUs financial
"Shares sold to satisfy the tax obligations...in connection with the settlement of previously vested RSUs."
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
ESPP financial
"Includes 1,792 shares acquired under the ESPP Purchase on June 1, 2026."
An Employee Stock Purchase Plan (ESPP) is a company program that lets employees buy the company’s shares at a reduced price, usually by setting aside a small portion of their pay over time. It matters to investors because it encourages employees to own part of the business—like giving staff a discounted membership— which can boost commitment and performance, while also potentially increasing the number of shares available and affecting shareholder value.
indirect financial
"Indirect ownership of 523,749 shares is reported as held through a family trust."
trustee financial
"The shares are held of record by The Schuth Family Trust..., for which the Reporting Person serves as trustee."
A trustee is a person or institution legally appointed to hold and manage assets or enforce an agreement on behalf of other people (beneficiaries). Think of a trustee as a neutral referee or custodian who must act in the beneficiaries’ best interests, follow the trust or contract rules, and handle distributions, recordkeeping and enforcement. Investors care because a trustworthy trustee protects their rights, ensures promised payments or remedies are delivered, and can influence recoveries if things go wrong.

FAQ

What insider transaction did Denali Therapeutics (DNLI) report for Alexander O. Schuth?
Alexander O. Schuth reported a sale of 2,857 DNLI shares of common stock on 2026-08-11 at $25.07 per share. A footnote explains the sale covered tax obligations from previously vested RSUs.

How many Denali Therapeutics (DNLI) shares does Alexander O. Schuth hold after this transaction?
After the reported sale, Alexander O. Schuth directly holds 281,763 DNLI shares and indirectly holds 523,749 shares via a family trust. The direct holdings include 135,475 unvested RSUs and 1,792 ESPP shares acquired on June 1, 2026.

Was the Denali Therapeutics (DNLI) insider sale made under a Rule 10b5-1 trading plan?
No. The Form 4 for Denali Therapeutics (DNLI) indicates the Rule 10b5-1 checkbox is not selected. The sale of 2,857 shares is instead described as satisfying tax obligations from previously vested RSUs.

What was the price of the Denali Therapeutics (DNLI) shares sold by Alexander O. Schuth?
The reported sale price for the 2,857 DNLI shares was $25.07 per share. The transaction code is S, indicating an open market or private sale, with a related footnote describing its tax-settlement purpose.

How are Alexander O. Schuth’s indirect Denali Therapeutics (DNLI) holdings structured?
The Form 4 shows 523,749 DNLI shares held indirectly by The Schuth Family Trust U/A DTD 06/05/2017, for which Alexander O. Schuth serves as trustee. These are reported as indirect ownership on the form.

What RSU and ESPP positions does Alexander O. Schuth have in Denali Therapeutics (DNLI)?
His reported direct holdings include 135,475 unvested RSUs and 1,792 shares acquired under the ESPP on June 1, 2026. These are part of the total 281,763 directly held shares after the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Schuth Alexander O.
(Last)(First)(Middle)
C/O DENALI THERAPEUTICS INC.
161 OYSTER POINT BLVD.
(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Denali Therapeutics Inc. [ DNLI ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
COFO and Secretary
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/11/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/11/2026S(1)2,857D$25.07281,763(2)(3)D
Common Stock523,749ISee footnote(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested RSUs.
2. Includes 135,475 Unvested RSUs.
3. Includes 1,792 shares acquired under the ESPP Purchase on June 1, 2026.
4. The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.
Remarks:
/s/ Tyler Nielsen, by power of attorney08/13/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR